Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693546 | 0.83 | FFAR1 (0.49) | BRD4PTGS2PTGS1GHSRVNN1 | |
| SCHEMBL6691549 | 0.82 | TP53 (0.48) | KMT2AMEN1LMNAMAPT | |
| SCHEMBL7208469 | 0.81 | MAPT (0.39) | BRD4KMT2APPARAMEN1LMNA | |
| SCHEMBL6692382 | 0.81 | PTGS2 (0.51) | BRD4PTGS2PTGS1GHSRVNN1 | |
| SCHEMBL6695981 | 0.78 | LMNA (0.51) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL6696110 | 0.78 | RXFP1 (0.46) | BRD4PTGS2PTGS1GHSRVNN1 | |
| SCHEMBL6693953 | 0.75 | MAPT (0.65) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL6693419 | 0.75 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL15078830 | 0.75 | NR1H2 (0.64) | PTGS2NR1H2NR1H3VNN1MAPT | |
| SCHEMBL6691735 | 0.74 | CA1 (0.60) | PTGS2GHSRGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | 4SC AG (DE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003076388-A2 | BIS-ANILINE DERIVATIVES USEFUL AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | PAH, PNMT, OPRM1 | BRD4 878/4885PTGS2 2364/4885NR1H2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.